Related Experiment Videos
Lambert-Eaton myasthenic syndrome.
1Department of Clinical Neurology, University of Oxford, Grande-Bretagne. john.newsomdavis@btinternet.com
Revue Neurologique
|March 23, 2004
Summary
Lambert-Eaton Myasthenic Syndrome (LEMS) causes muscle weakness and autonomic issues, often linked to lung cancer. Diagnosis involves specific antibodies and electrophysiological tests, with treatments like 3,4-diaminopyridine offering benefits.
Area of Science:
- Neurology
- Immunology
- Oncology
Background:
- Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder.
- Characterized by proximal muscle weakness, autonomic dysfunction, and reflex abnormalities.
- Often associated with small cell lung cancer (SCLC) in a paraneoplastic form (P-LEMS).
Purpose of the Study:
- To summarize the key features, pathophysiology, diagnosis, and management of LEMS.
- To differentiate between paraneoplastic and non-paraneoplastic LEMS.
- To highlight treatment strategies for improving patient outcomes.
Main Methods:
- Review of clinical characteristics, diagnostic criteria, and treatment options for LEMS.
- Discussion of the role of autoantibodies against P/Q-type voltage-gated calcium channels (VGCCs).
- Electrophysiological studies including compound muscle action potential (CMAP) amplitude assessment.
Main Results:
- LEMS presents with proximal weakness, autonomic symptoms, and unique electrophysiological findings.
- Autoantibodies to VGCCs are the primary cause, triggered by tumors in P-LEMS.
- 3,4-diaminopyridine is effective, while tumor treatment can improve P-LEMS symptoms.
Conclusions:
- LEMS diagnosis relies on clinical presentation, serology for VGCC antibodies, and electrophysiology.
- Effective management involves symptomatic treatment, immunotherapy, and addressing underlying malignancy in P-LEMS.
- Long-term control can be achieved with various therapeutic approaches.